EXAMINE THIS REPORT ON MBL77

Other than ibrutinib, people with M-CLL, devoid of TP53 aberrations and fit ample to tolerate FCR therapy, may still be great candidates for that latter, with the advantage being that this treatment method may be accomplished in 6 months when ibrutinib must be taken indefinitely. This feature would be especially valuable for non-compliant people or